These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6222093)

  • 1. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison.
    Jouvent R; Abensour P; Bonnet AM; Widlocher D; Agid Y; Lhermitte F
    J Affect Disord; 1983 May; 5(2):141-5. PubMed ID: 6222093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study.
    LeWitt PA; Gopinathan G; Ward CD; Sanes JN; Dambrosia JM; Durso R; Calne DB
    Neurology; 1982 Jan; 32(1):69-72. PubMed ID: 7033825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine in the management of end of dose deterioration in Parkinson's disease.
    Grimes JD; King DB; Kofman OS; Molina-Negro P; Wilson AF; Bouchard S
    Can J Neurol Sci; 1984 Nov; 11(4):452-6. PubMed ID: 6518428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine and Parkinson's disease: a 16-hour clinical evaluation.
    Grøn U; Friis ML; Pakkenberg H
    Acta Neurol Scand; 1980 Feb; 61(2):131-6. PubMed ID: 6994422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
    Laihinen A; Rinne UK; Suchy I
    Acta Neurol Scand; 1992 Dec; 86(6):593-5. PubMed ID: 1481646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Kanazawa I; Goto I; Iwata M; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1990; 30 Suppl 1():3-8. PubMed ID: 2178938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine treatment of depressive disorders. Clinical and biochemical effects.
    Nordin C; Siwers B; Bertilsson L
    Acta Psychiatr Scand; 1981 Jul; 64(1):25-33. PubMed ID: 6172006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
    Factor SA; Sanchez-Ramos JR; Weiner WJ
    J Neurol Neurosurg Psychiatry; 1988 Apr; 51(4):529-33. PubMed ID: 3288717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second interim report of the nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Iwata M; Goto I; Kanazawa I; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1989; 29 Suppl 1():3-8. PubMed ID: 2714305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
    Rinne UK
    Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pergolide and bromocriptine therapy in parkinsonism.
    LeWitt PA; Ward CD; Larsen TA; Raphaelson MI; Newman RP; Foster N; Dambrosia JM; Calne DB
    Neurology; 1983 Aug; 33(8):1009-14. PubMed ID: 6348585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine: low-dose therapy in Parkinson disease.
    Teychenne PF; Bergsrud D; Racy A; Elton RL; Vern B
    Neurology; 1982 Jun; 32(6):577-83. PubMed ID: 7201089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A; Paggi A; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients.
    Waehrens J; Gerlach J
    J Affect Disord; 1981 Jun; 3(2):193-202. PubMed ID: 6454713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression.
    Theohar C; Fischer-Cornelssen K; Brosch H; Fischer EK; Petrovic D
    Arzneimittelforschung; 1982; 32(7):783-7. PubMed ID: 6751339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M; Angrist B; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.